A Single Center Pilot Study on the Use of a Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
This study aims to gather initial data on the potential effectiveness of a transcutaneous auricular vagal nerve stimulation device in patients diagnosed with chronic kidney disease. The study participants will receive a 15-minute session of transcutaneous auricular vagal nerve stimulation at one of two specified doses, assigned alternatively. Prior to and after the stimulation, vital signs, heart rate variability, and autonomic function will be monitored. Our primary aims are to investigate the feasibility of the protocol and generate preliminary signals of efficacy and tolerability for two different doses of vagal nerve stimulation. The pilot estimates will be used to design a larger scale study that may lead to potentially targeted interventions to reduce CV mortality in the CKD population.
A single-center prospective observational study of post-discharge outcomes and function among patients treated for severe COVID-19 disease
This is a single-center observational study that aims to examine physical and mental function of patients treated for severe COVID-19 disease at NYU Langone Health one month post-discharge. We will use telephone interviews with patients to characterize their overall health state, physical function, breathlessness, mood, social support and post-discharge challenges. We will use chart review to identify patient demographics, comorbidities, and clinical condition, and to identify treatments received. Our target enrollment is 500 patients.
A single-center randomized clinical trial to test the efficacy of pharyngeal swallowing exercises (with or without protein supplementation) to build pharyngeal muscular reserve in pre-frail older adults
The swallowing muscles are prone to decreased strength and function as part of the natural aging process which can lead to difficulty swallowing, malnutrition, and frailty. Exercise and nutrition are powerful stimulators of muscular change. The proposed research will investigate the effectiveness of a 12-week proactive regimen of swallowing exercises (with or without daily protein supplement drinks) to improve the composition, force, and physiology of the swallowing muscles and explore the relationship to overall health and physical function in 80 community-dwelling older adults. Each participant will serve as their own control for 12 weeks before being randomized to complete swallowing exercises alone or swallowing exercises with protein drinks.
A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants with Type 2 Diabetes Mellitus Protocol Number: I8H-MC-BDDB
The purpose of this research study is find out about the safety and tolerability of an experimental drug (LY3209590) for the treatment of pediatric type 2 diabetes mellitus (T2DM) which is a once weekly treatment option. This study will last about 100 days and will involve about 8 visits. Participants will be administered a single dose of a study drug as an injection their belly. Participants will be asked to monitor their glucose levels using a glucose meter provided by the study team.
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
This study is examining how well a new treatment called N-803, combined with a standard treatment called BCG, works compared to just using BCG alone in patients who haven't had BCG before and have a specific type of bladder cancer that hasn't spread into the muscle. There are two groups of patients in the study: one group has a more serious form of the cancer, and the other group has a less serious form. Every patient in the study will get either N-803 and BCG or just BCG through a tube into the bladder for six weeks. After that, the doctors will check how well the treatment is working. If it's going well, some patients will keep getting more treatments to help keep the cancer from coming back. The study will follow patients for about three years to see how they're doing.
A Study to Evaluate PF-06823859 in People With Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis or Polymyositis)
The purpose of this research study is to learn about the effects of the study drug PF-06823859 for treating dermatomyositis (DM) or polymyositis (PM).
A Transdiagnostic Study of Emotional Impulsivity in Suicidal Ideation and Behavior
The purpose of this research study is to understand and learn more about why some people with schizophrenia or depression are more likely to think about or attempt suicide than others. One way to study this issue is by comparing people with schizophrenia or depression with high and low levels of suicidal thoughts and attempts. This study will involve clinical interviews, questionnaires, cognitive testing, and MRI scanning.
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion A Randomized Multicenter Study
The purpose of this research study is to determine if the IMPEDE-FX RapidFill System is safe and helps to shrink abdominal aortic aneurysm (AAA) sacs after an endovascular stent graft has been placed.
AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3
This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Abdominal Core Health & Hernia Program | NYU Langone Health
NYU Langone’s Abdominal Core Health and Hernia Program provides simple and complex hernia repair and abdominal wall reconstruction.